Senior Associate
Los Angeles
Dr. Christopher Lynch brings over a decade of experience litigating and prosecuting patents in the biotechnology, pharmaceutical, and medical device spaces to his intellectual property practice, which focuses on complex patent litigation, post-grant proceedings, and appeals.
Dr. Lynch's practice centers on representing clients involved in patent litigation and appeals, as well as U.S. Patent and Trademark Office post-grant proceedings. His experience encompasses numerous aspects of the life sciences, including small and large molecule pharmaceuticals, cellular immunotherapies, medical devices, and diagnostics. He has represented biopharmaceutical clients of all sizes, from start-ups to multinational corporations.
Dr. Lynch also counsels clients on pre-litigation strategies relating to their intellectual property, offering advice on matters including patentability, freedom-to-operate, patent prosecution and portfolio management, and licensing.
Dr. Lynch received his J.D. from Loyola Law School, where he graduated #1 in the evening program and top 5% overall while working for another international law firm.
Before law school, Dr. Lynch earned his Ph.D. in cell biology from Columbia University. His dissertation examined the biophysical aspects of cellular motility using advanced microscopy and imaging techniques.
Tris Pharma, Inc. v. Teva Pharmaceuticals USA, Inc.: Represented Tris in a successful Hatch-Waxman action in the District of New Jersey related to Tris's QuilliChew ER® product.
TMT Systems, Inc. v. Medtronic Inc.: Represented TMT in district court litigation in the Western District of Texas and at the Federal Circuit.
Novartis Vaccines and Diagnostics, Inc. et al. v. Genentech, Inc.: Represented Genentech in district court litigation in the Northern District of California.
Genentech, Inc. v. Amgen, Inc.: Represented Amgen in a Biologics Price Competition and Innovation Act action in the District of Delaware related to Amgen's Mvasi® biosimilar of Genentech's Avastin®.